Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130962 · ClinicalTrials.gov registry record · Phase 2
ALGRX 4975 in the Treatment of Patients With Morton's Neuroma
A Phase 2 study of Neuroma, sponsored by AlgoRx Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00130962: Completed Phase 2 study of Neuroma, sponsored by AlgoRx Pharmaceuticals.
NCT00130962 is a Phase 2 study of Neuroma that has completed, run by AlgoRx Pharmaceuticals. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00130962, a Phase 2 study of Neuroma, has completed, sponsored by AlgoRx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.
Conditions Studied
Interventions
- DRUG ALGRX 4975
Study Locations (2)
Maryland
- Crossroads Research, Inc. - Owings Mills
Utah
- Jean Brown Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
What the finished NCT00130962 record still lists
NCT00130962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Neuroma appearing as the primary indexed condition, and to 1 intervention - of which ALGRX 4975 is the first listed.
NCT00130962 reports a single indexed study location in Maryland, Utah.
Frequently Asked Questions
What is clinical trial NCT00130962 about?
NCT00130962 is a clinical study titled "ALGRX 4975 in the Treatment of Patients With Morton's Neuroma". Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects w...
What is the current status of trial NCT00130962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-09. Estimated completion is 2006-02.
What conditions does trial NCT00130962 study?
This clinical trial studies the following conditions: Neuroma.
What interventions are being tested in trial NCT00130962?
The interventions under investigation include: ALGRX 4975 (DRUG).
Who is sponsoring clinical trial NCT00130962?
This trial is sponsored by AlgoRx Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00130962 being conducted?
This trial has 2 study locations across Maryland, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00130962's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia